Novavax , Inc. (NASDAQ:NVAX), a biotechnology company specializing in the development of vaccines with a market capitalization of $1.32 billion, has had a key contract with the Canadian government ...

Market forces rained on the parade of Novavax, Inc. (NASDAQ:NVAX) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) forecasts ...

Novavax (NasdaqGS:NVAX) recently announced its earnings for Q4 2024, showing a significant improvement in net loss and loss per share, which may have positively influenced its stock price movement.

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

Novavax reported a Q4 2024 EPS of -$0.51, surpassing expectations. Revenue for the quarter fell to $88.3 million, missing forecasts and down from $291 million in Q4 2023. The company reduced R&D and ...

Novavax has begun a late-stage trial of its experimental COVID-19 vaccine in the UK, which could support filings for a licence in the UK, EU and other countries.

If passed, anyone who provides or administers a gene-based vaccine to another person would face a penalty of $500 per violation.

Jasmine joined Newsweek in 2024 from News UK and had previously written for ... use mRNA technology in their COVID-19 vaccines, but Novavax uses a protein-based vaccine. It is the only non-mRNA ...

Healthcare & Pharmaceuticalscategory· February 28, 2025 UK health regulator approves ... on the drugmaker's manufacturing plant in India. Novavax sees royalties, reduced expenses on COVID ...

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...